Febrile mucositis in haematopoietic SCT recipients

Bone Marrow Transplantation

Volumn 43, Issue 1, 2009, Pages 55-60

  van der Velden, W J F M ^a   Blijlevens, N M A ^a   Feuth, T ^b   Donnelly, J P ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CITRULLINE; MELPHALAN;

ADULT; ARTICLE; BACTEREMIA; CONTROLLED STUDY; FEBRILE MUCOSITIS; FEMALE; GRAFT REJECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MYELOMA; NEUTROPENIA; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, ALKYLATING; BACTEREMIA; C-REACTIVE PROTEIN; CITRULLINE; COHORT STUDIES; COMBINED MODALITY THERAPY; FEMALE; FEVER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; NEUTROPENIA; RETROSPECTIVE STUDIES; STOMATITIS;

EID: 58549087133     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.270     Document Type: Article

References (25)

1. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64: 328-340.
2. de Pauw BE, Deresinski SC, Feld R, Lane-Allman EF, Donnelly JP. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. The Intercontinental Antimicrobial Study Group. Ann Intern Med 1994; 120: 834-844.
3. Furno P, Bucaneve G, Del FA. Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment of febrile neutropenic patients: A meta-analysis. Lancet Infect Dis 2002; 2: 231-242.
4. Dekker A, Bulley S, Beyene J, Dupuis LL, Doyle JJ, Sung L. Meta-analysis of randomized controlled trials of prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor after autologous and allogeneic stem cell transplantation. J Clin Oncol 2006; 24: 5207-5215.
5. Berghmans T, Paesmans M, Lafitte JJ, Mascaux C, Meert AP, Jacquy C et al. Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysis. Support Care Cancer 2002; 10: 181-188.
6. From the Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Report of a consensus panel. J Infect Dis 1990; 161: 397-401.
7. Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 2004; 100 (9 Suppl): 1995-2025.
8. Blijlevens NM. Implications of treatment-induced mucosal barrier injury. Curr Opin Oncol 2005; 17: 605-610.
9. Blijlevens NM, Donnelly JP, de Pauw BE. Mucosal barrier injury: Biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: An overview. Bone Marrow Transplant 2000; 25: 1269-1278.
10. Marron A, Carratala J, Gonzalez-Barca E, Fernandez-Sevilla A, Alcaide F, Gudiol F. Serious complications of bacteremia caused by Viridans streptococci in neutropenic patients with cancer. Clin Infect Dis 2000; 31: 1126-1130.
11. Costa SF, Miceli MH, Anaissie EJ. Mucosa or skin as source of coagulase-negative staphylococcal bacteraemia? Lancet Infect Dis 2004; 4: 278-286.
12. Ruescher TJ, Sodeifi A, Scrivani SJ, Kaban LB, Sonis ST. The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. Cancer 1998; 82: 2275-2281.
13. Blijlevens NM, Donnelly JP, de Pauw BE. Impaired gut function as risk factor for invasive candidiasis in neutropenic patients. Br J Haematol 2002; 117: 259-264.
14. Elting LS, Shih YC. The economic burden of supportive care of cancer patients. Support Care Cancer 2004; 12: 219-226.
15. MacGregor RR, Beaty HN. Evaluation of positive blood cultures. Guidelines for early differentiation of contaminated from valid positive cultures. Arch Intern Med 1972; 130: 84-87.
16. Potting CM, Blijlevens NA, Donnelly JP, Feuth T, van Achterberg T. A scoring system for the assessment of oral mucositis in daily nursing practice. Eur J Cancer Care (Engl) 2006; 15: 228-234.
17. Blijlevens NM, Lutgens LC, Schattenberg AV, Donnelly JP. Citrulline: A potentially simple quantitative marker of intestinal epithelial damage following myeloablative therapy. Bone Marrow Transplant 2004; 34: 193-196.
18. Crenn P, Vahedi K, Lavergne-Slove A, Cynober L, Matuchansky C, Messing B. Plasma citrulline: A marker of enterocyte mass in villous atrophy-associated small bowel disease. Gastroenterology 2003; 124: 1210-1219.
19. Blijlevens NM, Donnelly JP, DePauw BE. Inflammatory response to mucosal barrier injury after myeloablative therapy in allogeneic stem cell transplant recipients. Bone Marrow Transplant 2005; 36: 703-707.
20. Tsuji E, Hiki N, Nomura S, Fukushima R, Kojima J, Ogawa T et al. Simultaneous onset of acute inflammatory response, sepsis-like symptoms and intestinal mucosal injury after cancer chemotherapy. Int J Cancer 2003; 107: 303-308.
21. Mullighan CG, Bardy PG. New directions in the genomics of allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007; 13: 127-144.
22. Slavin MA, Grigg AP, Schwarer AP, Szer J, Spencer A, Sainani A et al A randomized comparison of empiric or pre-emptive antibiotic therapy after hematopoietic stem cell transplantation. Bone Marrow Transplant 2007; 40: 157-163.
23. Offidani M, Corvatta L, Olivieri A, Rupoli S, Frayfer J, Mele A et al Infectious complications after autologous peripheral blood progenitor cell transplantation followed by G-CSF. Bone Marrow Transplant 1999; 24: 1079-1087.
24. Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004; 351: 2590-2598.
25. Parker JE, Shafi T, Pagliuca A, Mijovic A, Devereux S, Potter M et al Allogeneic stem cell transplantation in the myelodysplastic syndromes: Interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens. Br J Haematol 2002; 119: 144-154.